Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 216

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 216
---
527 | ) |
| Present value of future minimum lease payments                                            |     |   |  366,430 |   |
| Less current portion of operating lease liability                                         |     |   |  (70,713 | ) |
| Operating lease liability, net of current portion                                         |     | $ |  295,717 |   |

Total cash paid for amounts included in the measurement of lease liabilities
were approximately $88,000 and $49,000 for the nine months ended March 31, 2025 and 2024, respectively.

The weighted average remaining lease term and discount
rate as of March 31, 2025 and June 30, 2024 were as follows:

| Schedule of weighted average remaining lease term and discount rate |     |     | March 31, 2025 |   |     |     | June 30, 2024 |   |
|:--------------------------------------------------------------------|:----|:----|---------------:|:--|:----|:----|--------------:|:--|
| Weighted average remaining lease term (Years)                       |     |     |                |   |     |     |               |   |
| Operating lease                                                     |     |     |            3.8 |   |     |     |           4.6 |   |
| Weighted average discount rate                                      |     |     |                |   |     |     |               |   |
| Operating lease                                                     |     |     |          15.00 | % |     |     |         15.00 | % |

F-41

| 10. | Commitments and Contingencies |

Royalty Agreements

Pursuant to the Agreement and Plan of Merger entered
into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay
a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members,
PharmaIn Corporation, and The Barrett Edge, Inc.

Pursuant to the Technology Transfer Agreement entered
into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit
royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped